Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Results of a Phase 1/2a dose–escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • بيانات النشر:
      Informa UK Limited, 2020.
    • الموضوع:
      2020
    • نبذة مختصرة :
      FF-10501-01 potently inhibits inosine-5-monophosphate dehydrogenase (IMPDH), inducing anti-proliferative and pro-apoptotic effects in acute myeloid leukemia (AML) human cell lines resistant to hypomethylating agents. In this Phase 1/2a study, Phase 1 enrolled 38 patients with relapsed/refractory AML (
    • ISSN:
      1029-2403
      1042-8194
    • الرقم المعرف:
      10.1080/10428194.2020.1747065
    • الرقم المعرف:
      edsair.doi.dedup.....ab18f7fee86d76cbc539c840133535fa